US panel rejects Forest, Nycomed lung drug

US FDA Panel now says “data do not support approval of Forest, Nycomed lung drug Daxas for COPD maintenance.” FDA advisers voted 10-5 against recommending approval. Shares of Forest (FRX) diving on that news…trading AH at $29.40, -$3.06 (-9.43%) – Reuters

Be the first to comment

Leave a Reply

Your email address will not be published.